Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Microalbuminuria and hypertension.

G Reboldi1, G Gentile, F Angeli

  • 1Department of Internal Medicine, University of Perugia, Perugia, Italy. paolo@unipg.it

Minerva Medica
|September 24, 2005
PubMed
Summary

Microalbuminuria (MAU), an early sign of kidney disease, is a valuable marker for cardiovascular risk in hypertension. Early detection and treatment, particularly with ACE inhibitors, can reduce urinary albumin excretion (UAE) and improve outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of germline mutations in non-small cell lung cancer: A systematic review of emerging genetic drivers and clinical implications.

Critical reviews in oncology/hematology·2026
Same author

20th anniversary of adjuvant trastuzumab: reflections on a breakthrough moment.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge.

ESMO open·2025
Same author

Effective and safe use of alirocumab in spinal and bulbar muscular atrophy with high cardiovascular risk: a case report.

European review for medical and pharmacological sciences·2025
Same author

Care pathway of asylum seekers in the health care access points following inclusion in the PREMENTADA project: an observational study.

Public health·2024
Same author

Efficacy and safety of BNT162b2 mRNA vaccine in a cohort of 90 transfusion dependent thalassemia patients.

Transfusion medicine (Oxford, England)·2024

Area of Science:

  • Nephrology
  • Cardiology
  • Hypertension Research

Background:

  • Microalbuminuria (MAU), defined as elevated urinary albumin excretion (UAE) below proteinuric levels, is a recognized marker for kidney disease and cardiovascular risk in diabetes.
  • MAU is also associated with cardiovascular risk factors, target organ damage, and cardiovascular disease in the general population and individuals with essential hypertension.
  • The prevalence of MAU in essential hypertension varies widely due to factors like UAE variability, age, ethnicity, measurement techniques, and differing MAU definitions.

Purpose of the Study:

  • To review the clinical value of microalbuminuria (MAU) in subjects with essential hypertension.
  • To examine the association between UAE and cardiovascular risk factors, target organ damage, and cardiovascular disease in hypertensive patients.
  • To evaluate the impact of antihypertensive treatments on UAE and discuss the role of MAU in hypertension management.

Related Experiment Videos

Main Methods:

  • Review of available clinical evidence and prospective studies on MAU in essential hypertension.
  • Analysis of associations between UAE, blood pressure (BP), left ventricular mass, and other cardiovascular risk factors.
  • Evaluation of the impact of antihypertensive treatments, including ACE inhibitors and angiotensin II receptor antagonists, on UAE.

Main Results:

  • A direct, continuous association exists between UAE, BP, and left ventricular mass in most studies.
  • Prospective studies show an association between MAU and future cardiovascular disease risk, with increased event incidence even below conventional MAU thresholds.
  • Antihypertensive treatment, especially with ACE inhibitors and angiotensin II receptor antagonists, effectively reduces UAE.

Conclusions:

  • MAU serves as a marker integrating multiple detrimental factors affecting the cardiovascular system, beyond being a direct risk factor for renal damage.
  • MAU determination is recommended in the initial assessment of essential hypertension patients, aligning with European hypertension guidelines.
  • Periodic evaluation of MAU is suggested as a valuable and cost-effective predictive marker in hypertension management.